ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Data ReadoutpositiveICOTYDEPositive

AI Analysis

Summary

Johnson & Johnson announced one-year data from ICOTYDE (icotrokinra) trials demonstrating sustained skin clearance in plaque psoriasis patients, with nearly 60% of adolescents achieving complete skin clearance at Week 52 in the ICONIC-LEAD study.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

One-year results from ICONIC-ADVANCE 1 and 2 studies showing high rates of complete skin clearance at Week 24 and Week 52. Nearly 60% of adolescents in ICONIC-LEAD study achieved completely clear skin at Week 52.

Importance:6/10

Sentiment:

0.75

dermatologypsoriasisoral medicationclinical dataadolescents

Related Companies

$JNJ

Read the original article

Published by PR Newswire Pharma on March 28, 2026 2:00 PM

Read Original